Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

The Value of Drug–Drug Interaction Risk Assessments

Posted on June 28th, 2017 by

Pharma R&D

phamapendium

Should a drug candidate move on to pre-clinical and clinical trials? It’s a question that every pharmaceutical developer must face, and the earlier they can answer it, the better in terms of use of time and effort. Continue reading “The Value of Drug–Drug Interaction Risk Assessments” »

Leveling the Playing Field in Medicinal Chemistry

Posted on June 26th, 2017 by

Chemistry

Reaxys MC

For the designers and developers of Elsevier’s R&D Solutions, a major concern is ensuring that each solution makes the same level of searching or analytical power available to all users. The primary aim for the teams is to Continue reading “Leveling the Playing Field in Medicinal Chemistry” »

The Hive is open for 2017 applicants

Posted on June 23rd, 2017 by

Pharma R&D

The hive

It’s been over a year since Elsevier first launched The Hive, and we are inspired by the results that we have seen from this venture. Through frequent blog posts and video interviews, we and everyone who followed the project have been able to see the progress made by the four participating companies: Continue reading “The Hive is open for 2017 applicants” »

The Liabilities of Pharmacovigilance Activities

Posted on June 21st, 2017 by

Pharmacovigilance

legal

There is always a risk that any Pharmacovigilance (PV) activity, even executed with the highest business and ethical standards, and with the highest compliance results, could be challenged, sometimes many years later. As a member of a PV team, you may have to one day justify your actions in front of a group of plaintiff’s lawyers, Continue reading “The Liabilities of Pharmacovigilance Activities” »

So-Called Rare Diseases Are Too Common to Ignore

Posted on June 19th, 2017 by

Pharma R&D

Pills in hand

It’s time to re-think our attitude towards rare diseases. Even though relatively few people suffer from any given rare disease, there are so many of these maladies that it’s a surprisingly large swath of the population that is actually victimized by them. Continue reading “So-Called Rare Diseases Are Too Common to Ignore” »

Connecting the data sources to understand the safety of bioactivities

Posted on June 16th, 2017 by

Pharma R&D

Digital_monitor-1307227__340

Earlier this week, I was in Berlin, Germany speaking for the Elsevier Professional Services team at the Drug Discovery Summit (Monday, June 12, 15:30) at the Hotel Palace Berlin on informatics analyses to provide early warning for clinical issues from bioassay results. Continue reading “Connecting the data sources to understand the safety of bioactivities” »

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. …
  7. 42


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.